HVHanne Vos

Hanne Vos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hanne Vos has a total of 94 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparison of ‘quilting sutures’ with ‘conventional sutures and drain placement’ after mastectomy: protocol for the BE-Quilt – a multicentre, pragmatic randomised controlled trial

    by Suzanna De Winter, Anaïs Brouckaert, Kathleen Lambein, Luna De Sutter, Annouschka Laenen, Ines Nevelsteen, Hanne Vos, Ann Smeets

  • Open Access

    Dissecting the immune infiltrate of primary luminal B‐like breast carcinomas in relation to age

    by Sigrid Hatse, Yentl Lambrechts, Asier Antoranz Martinez, Maxim De Schepper, Tatjana Geukens, Hanne Vos, Lieze Berben, Julie Messiaen, Lukas Marcelis, Yannick Van Herck, et al.

    The impact of aging on the immune landscape of luminal breast cancer (Lum‐BC) is poorly characterized. Understanding the age‐related dynamics of immune editing in Lum‐BC is anticipated to improve the therapeutic benefit of immunotherapy in older patients. To this end, here we applied the ‘multiple iterative labeling by antibody neo‐deposition’ (MILAN) technique, a spatially resolved single‐cell multiplex immunohistochemistry method. We created tissue microarrays by sampling both the tumor center and invasive front of luminal breast tumors collected from a cohort of treatment‐naïve patients enrolled in the prospective monocentric IMAGE (IMmune system and AGEing) study. Patients were subdivided into three nonoverlapping age categories (35–45 = ‘young’, n = 12; 55–65 = ‘middle’, n = 15; ≥70 = ‘old’, n = 26). Additionally, depending on localization and amount of cytotoxic T lymphocytes, the tumor immune types ‘desert’ (n = 22), ‘excluded’ (n = 19), and ‘inflamed’ (n = 12) were identified. For the MILAN technique we used 58 markers comprising phenotypic and functional markers allowing in‐depth characterization of T and B lymphocytes (T&B‐lym). These were compared between age groups and tumor immune types using Wilcoxon's test and Pearson's correlation. Cytometric analysis revealed a decline of the immune cell compartment with aging. T&B‐lym were numerically less abundant in tumors from middle‐aged and old compared to young patients, regardless of the geographical tumor zone. Likewise, desert‐type tumors showed the smallest immune‐cell compartment and were not represented in the group of young patients. Analysis of immune checkpoint molecules revealed a heterogeneous geographical pattern of expression, indicating higher numbers of PD‐L1 and OX40‐positive T&B‐lym in young compared to old patients. Despite the numerical decline of immune infiltration, old patients retained higher expression levels of OX40 in T helper cells located near cancer cells, compared to middle‐aged and young patients. Aging is associated with important numerical and functional changes of the immune landscape in Lum‐BC. © 2024 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.


  • Open Access

    Obesity-associated changes in molecular biology of primary breast cancer

    by Ha-Linh Nguyen, Tatjana Geukens, Marion Maetens, Samuel Aparicio, Ayse Bassez, Ake Borg, Jane Brock, Annegien Broeks, Carlos Caldas, Fatima Cardoso, et al.

    Obesity is associated with an increased risk of developing breast cancer (BC) and worse prognosis in BC patients, yet its impact on BC biology remains understudied in humans. This study investigates how the biology of untreated primary BC differs according to patients’ body mass index (BMI) using data from >2,000 patients. We identify several genomic alterations that are differentially prevalent in overweight or obese patients compared to lean patients. We report evidence supporting an ageing accelerating effect of obesity at the genetic level. We show that BMI-associated differences in bulk transcriptomic profile are subtle, while single cell profiling allows detection of more pronounced changes in different cell compartments. These analyses further reveal an elevated and unresolved inflammation of the BC tumor microenvironment associated with obesity, with distinct characteristics contingent on the estrogen receptor status. Collectively, our analyses imply that obesity is associated with an inflammaging-like phenotype. We conclude that patient adiposity may play a significant role in the heterogeneity of BC and should be considered for BC treatment tailoring.


  • Open Access

    Capturing age-related changes in the tumor microenvironment of luminal breast cancer using the multiplex immunohistochemistry technique, MILAN.

    by Yentl Lambrechts, Asier Antoranz Martinez, Maxim De Schepper, Tatjana Geukens, Hanne Vos, Lieze Berben, Julie Messiaen, Lukas Marcelis, Yannick Van Herck, Patrick Neven, et al.

  • Open Access

    Abstract P2-08-23: Early intratumoral changes after a single dose of anti-PD-1 treatment in patients with early breast cancer (BC)

    by Hanne Vos, Kathleen Lambein, François Richard, Ines Nevelsteen, Ayse Bassez, Diether Lambrechts, Kevin Punie, Hans Wildiers, Giuseppe Floris, Christine Desmedt, et al.

    Intro: Despite the growing success of immune checkpoint blockade in BC, the underlying mechanisms of response or resistance to these treatments is still poorly understood. We recently conducted a window-of-opportunity study (BioKey) including 54 patients with early BC (NCT03197389) in which patients were treated with one dose of pembrolizumab 10 ± 4 days before surgery. A tumor biopsy was taken before and after the administration of pembrolizumab. Using single-cell transcriptome profiling, we identified patients with clonotype expansion of PD-1-expressing T-cells after treatment with pembrolizumab (Bassez A, Vos H et al, Nature Medicine 2021). Expansion mainly involved CD8+ T - and CD4+ T cells. We designated these as patients with clonotype expansion or ‘expanders’ (E), whereas patients lacking clonotype expansion were considered ‘non-expanders’ (NE). In this study, we aimed at investigating the association between stromal tumor infiltrating lymphocytes (sTIL) and various immune markers using immunohistochemistry with the E phenotype. Methods: The BioKey trial has 2 cohorts. The first one included 39 treatment-naive patients who were scheduled for upfront surgery. The second cohort included 15 patients with an estimated residual tumor size of at least 1cm on imaging after neo-adjuvant chemotherapy. All molecular subtypes were represented: triple-negative (TN) BC (n= 18, 8 E and 10 NE), HER2-positive BC (n= 5, 1 E and 4 NE) and hormone receptor (HR)-positive/HER2-negative BC (n= 17, 3 E and 14 NE). 7 core biopsies and 5 resection slides were not contributive and were excluded. The expander status of 14 patients was unknown. sTIL were evaluated and immunohistochemical stains (CD3, CD4, CD8, CD68, CD73, FoxP3, Ki67, PD-1 and PD-L1) were performed. Associations between expander status and biomarkers were assessed using firth logistic regressions, adjusting per cohort. Biomarkers were considered as continuous variables and Odds Ratio computed per one unit increase on a non-transformed scale. Given the low number of E in cohort B, subgroup analyses were performed only in cohort A. Results: We observed that 1) higher levels of sTIL, PD-1+ sTIL and FOXP3+ cells in the pre-treatment biopsies, 2) higher levels of sTIL, PD1+ sTIL, PD-L1+, CD3+, CD4+, CD8+, CD68+, FOXP3+ cells and Ki67 in the post-treatment surgical specimen, as well as, 3) higher delta values (surgical specimen - biopsy) of sTIL, CD3+, CD4+, CD8+, CD68+ and Ki67 are associated with the E phenotype (Table 1). With regard to the subgroup analyses, we observed that higher levels of PD-1+ sTIL and CD68+ cells at diagnosis and surgery respectively, as well as higher delta values for CD68+, Ki67 and sTIL were associated with the E phenotype in HR+/HER2- BC, while high levels of FOXP3+ cells and PD-1+ sTILs in the biopsies, high levels of sTIL, CD3+, CD4+, CD8+, CD68+, FOXP3+, PD-1+ sTILs, PD-L1+ and Ki67 as well as higher delta values for PD-L1+ in the resection specimen were associated with the E phenotype in TNBC. Conclusion: We were able to detect associations between various cell populations of the tumor immune microenvironment evaluated before and after a single dose of pembrolizumab and the T-cell expansion phenotype previously defined at the single-cell level. It highlights the possible clinical utility of a biopsy taken early during treatment. Future neo-adjuvant studies will allow the validation of our findings and investigate the association between T-cell expansion and clinical outcomes. Citation Format: Hanne Vos, Kathleen Lambein, François Richard, Ines Nevelsteen, Ayse Bassez, Diether Lambrechts, Kevin Punie, Hans Wildiers, Giuseppe Floris, Christine Desmedt, Ann Smeets. Early intratumoral changes after a single dose of anti-PD-1 treatment in patients with early breast cancer (BC) [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P2-08-23.


  • Open Access

    Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer

    by Hanne Vos, Kathleen Lambein, François Richard, Bram Mariën, Ines Nevelsteen, Kevin Punie, Hans Wildiers, Lieze Berben, Annouschka Laenen, Giuseppe Floris, et al.

    The vast majority of studies investigating immune checkpoint inhibition (ICI) in patients with breast cancer have focused on triple-negative breast cancer (TNBC). In this study, we compared the tumor immune microenvironment (TIME) between TNBC and hormone receptor-negative HER2-positive breast cancer based on a selection of immune markers at the protein level in an institutional retrospective series. Additionally, we performed a similar comparison using publicly available transcriptomics data. Altogether, the results show a comparable TIME in both groups, with possible implications for the use of ICI in patients with hormone receptor-negative HER2-positive breast tumors.


  • Open Access

    Blood Immunosenescence Signatures Reflecting Age, Frailty and Tumor Immune Infiltrate in Patients with Early Luminal Breast Cancer

    by Lieze Berben, Asier Antoranz, Cindy Kenis, Ann Smeets, Hanne Vos, Patrick Neven, Giuseppe Floris, Hans Wildiers, Sigrid Hatse

    Background: Immune/senescence-related host factors play a pivotal role in numerous biological and pathological process like aging, frailty and cancer. The assessment of these host factors via robust, non-invasive, and easy-to-measure blood biomarkers could improve insights in these processes. Here, we investigated in a series of breast cancer patients in which way single circulating biomarkers or biomarker panels relate to chronological age, frailty status, and tumor-associated inflammatory microenvironment. Methods: An extensive panel of blood immune/senescence markers and the tumor immune infiltrate was studied in young, middle-aged, and old patients with an early invasive hormone-sensitive, HER2-negative breast cancer. In the old group, clinical frailty was estimated via the G8-scores. Results: Several three-blood biomarker panels proved to be able to separate old chronological age from young age very efficiently. Clinically more important, several three-blood biomarker panels were strongly associated with clinical frailty. Performance of blood biomarker panels for prediction of the tumor immune infiltrate was lower. Conclusion: Immune/senescence blood biomarker panels strongly correlate with chronological age, and clinically more importantly with frailty status in early breast cancer patients. They require further investigation on their ability to provide a more complete picture on clinical frailty status and direct personalized therapy in older persons.


  • Immune-related adverse events after a single dose of pembrolizumab

    by Hanne Vos, Kathleen Lambein, Hans Wildiers, Kevin Punie, Ann Smeets